France
Curium Pharma, a frontrunner in the nuclear medicine sector, is spearheading advancements in cancer diagnosis and treatment. Founded in 2017 and headquartered in France, the company is renowned for its life-changing radiopharmaceutical products that target Neuroendocrine Tumors (NETs) and prostate cancer PSMA.
With its slogan, "Redefining the experience of cancer through our trusted legacy in nuclear medicine," Curium Pharma builds on a strong foundation of delivering reliable solutions to patients globally. As part of its ambitious 2030 vision, the company plans to expand its presence in Japan and China, emphasizing its oncology focus and leveraging AI to enhance diagnostic image quality and accuracy.
Although Curium Pharma has not yet disclosed any recent investment activities, its commitment to revolutionary diagnostics and therapeutics, combined with superior service, positions it as a compelling opportunity for investors seeking to back life-changing innovations in the pharmaceutical industry.
Shorla Oncology